Perspective Therapeutics (NYSE:CATX) Earns Outperform Rating from Oppenheimer

Oppenheimer restated their outperform rating on shares of Perspective Therapeutics (NYSE:CATX) in a research report sent to investors on Friday, Benzinga reports. They currently have a $22.00 price target on the stock.

CATX has been the subject of a number of other research reports. Royal Bank of Canada cut their target price on shares of Perspective Therapeutics from $29.00 to $27.00 and set an outperform rating for the company in a research report on Friday, August 16th. Bank of America initiated coverage on shares of Perspective Therapeutics in a research note on Thursday, July 25th. They set a buy rating and a $24.00 price objective on the stock. Truist Financial initiated coverage on shares of Perspective Therapeutics in a research note on Wednesday, September 25th. They set a buy rating and a $21.00 price objective on the stock. Cantor Fitzgerald reissued an overweight rating on shares of Perspective Therapeutics in a research note on Monday, September 9th. Finally, Wedbush initiated coverage on shares of Perspective Therapeutics in a research note on Tuesday, October 1st. They set an outperform rating and a $25.00 price objective on the stock. Eight research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of Buy and an average target price of $21.43.

Perspective Therapeutics Stock Down 4.5 %

Shares of CATX opened at $12.66 on Friday. The business’s 50-day simple moving average is $13.82. Perspective Therapeutics has a 12-month low of $2.20 and a 12-month high of $19.05.

Perspective Therapeutics (NYSE:CATX) last announced its earnings results on Monday, August 12th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.04. The business had revenue of $0.53 million for the quarter. As a group, research analysts anticipate that Perspective Therapeutics will post -0.87 earnings per share for the current year.

Hedge Funds Weigh In On Perspective Therapeutics

A number of large investors have recently bought and sold shares of CATX. Janus Henderson Group PLC purchased a new position in Perspective Therapeutics during the first quarter worth approximately $15,511,000. Affinity Asset Advisors LLC acquired a new stake in shares of Perspective Therapeutics in the first quarter worth $6,069,000. Vanguard Group Inc. increased its position in shares of Perspective Therapeutics by 34.6% in the first quarter. Vanguard Group Inc. now owns 17,780,106 shares of the company’s stock worth $21,158,000 after acquiring an additional 4,566,356 shares in the last quarter. Ally Bridge Group NY LLC acquired a new stake in shares of Perspective Therapeutics in the second quarter worth $3,951,000. Finally, WealthPLAN Partners LLC acquired a new stake in shares of Perspective Therapeutics in the second quarter worth $1,695,000. Hedge funds and other institutional investors own 54.66% of the company’s stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.